MRK · News · 20260825N
Medicare Drug Price Negotiation Litigation
Merck & Co., Inc. · 2026-08-25 · Importance 53 · Surprise 60 · In source text
A federal court rejected Merck’s challenge to the Inflation Reduction Act’s Drug Price Negotiation Program on August 25, 2026. The ruling upheld the U.S. government’s authority to negotiate Medicare Part D maximum fair prices for high-expenditure medicines lacking generic competition. Merck had argued that the program violated the Fifth and First Amendments; the decision leaves pharmaceutical companies exposed to negotiated-price reductions and significant penalties for non-compliance.
Key facts
- A federal court denied Merck & Co.'s challenge to the Inflation Reduction Act's Drug Price Negotiation Program, upholding the federal government's ability to negotiate drug prices for Medicare Part D. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | contingent | — | A federal court denied Merck & Co.'s challenge to the Inflation Reduction Act's Drug Price Negotiation Program, upholding the federal… |